Figure 1From: High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumorsEGFR expression in IGROV-1 cells. Expression of EGFR in IGROV-1 cells evaluated by FACS. Thin and bold lines represent Alexa Fluor 488-secondary antibody and Cetuximab, respectively.Back to article page